Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcTFirst phase 3 study of 225Ac-PSMA-617 + ARPI versus standard treatment in PSMA-positive metastatic castration-resistant prostate cancer
CTR20252315Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of actinium-225 PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Jul 2025; status: active.
02
Drugs
actinium-225 PSMA-617
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20252315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252315.